ShareValue scores for GUFICBIO.NSE: Valuation 40, Quality 44, Growth 32, Health 49.

GUFICBIO.NSE
NSE

Gufic Biosciences Limited

₹403.00(+2.19%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-7% to 10%
Valuation
40
Overvalued
Price vs Value
Quality
44
Moderate
Business Strength
Growth
32
Weak
Revenue & Earnings
Health
49
Moderate
Financial Stability
Momentum
61
Bullish
Price Trend

Company Details

About

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, and South America. The company manufactures APIs and bulk drugs, such as antifungals, anaethetics, immuno suppressants, anginotensin receptor blocker, and intermediates for antifungals. It also manufactures lyophilized injections for antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. Further, it engages in contract and bulk drug manufacturing business. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026